Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Will improve efficiencies in biologics manufacturing.
August 13, 2020
By: Contract Pharma
Contract Pharma Staff
CPI, an independent technology innovation center, is partnering with Perceptive Engineering and FujiFilm Diosynth Biotechnologies. The companies will develop a data-driven solution to improve efficiencies during downstream biologics processing, reducing the cost of manufacturing life-saving therapies. Biologics offer promising treatment options for disease areas with unmet clinical needs, and now represent seven of the top ten grossing drugs globally. As part of the Digital Integrated and Intelligent Continuous (bio)Manufacturing (DIICbM) project, CPI and its partners will develop new tools to accelerate workflows and integrate process analytical technology into CPI’s existing automated platform for continuous downstream bioprocessing. David Lovett, managing director at Perceptive Engineering, said, “By using advances in at-line process analytical technology, the DIICbM project will help to optimize end-to-end manufacturing processes at CPI’s National Biologics Manufacturing Center. With strategic guidance from world-leading partner FujiFilm Diosynth Biotechnologies, we are hugely excited by this project.” Utilizing Perceptive Engineering’s PharmaMV software, the partners will collect and analyze data from CPI’s automated platform to build a model that can identify and predict the degradation and failure of purification resins. Additional data to refine the model will be provided by FujiFilm Diosynth Biotechnologies. The resins used in the manufacture of biologics are extremely expensive, and failure not only means they must be replaced, but also leads to batches of drugs that do not meet quality standards. The model being developed will enable a much greater understanding of resin failure, and the partners are working to integrate it into CPI’s automated platform to provide real-time insights. This will enable early interventions, while promoting the development of better processes that avoid resin failure altogether. “Fully optimizing and automating continuous downstream processes is a vital part of streamlining biologics manufacture. Our facilities have the ideal combination of expertise and instrumentation to test and prove the innovative new technology that can achieve this,” commented Lucy Foley, Biologics business unit director at CPI. CPI was instrumental in identifying the funding streams available for the project and writing the initial proposal. Once a working model is developed, CPI will demonstrate proof-of-concept at its National Biologics Manufacturing Center in Darlington, UK, and it will also investigate the model’s transferability to other platforms.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !